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Abstract: In considering an overview of microRNA biology, it is useful to consider microRNAs as a
part of cellular communication. At the simplest level, microRNAs act to decrease the expression of
mRNAs that contain stretches of sequence complementary to the microRNA. This function can be
likened to the function of endogenous or synthetic short interfering RNA (siRNA). However,
microRNA function is more complicated and nuanced than this ‘on-off’ model would suggest. Further,
many microRNA targets are themselves non-coding RNAs. In this review, we will discuss the role of
microRNAs in shaping the proteome of the cell in a way that is consistent with microRNA involvement
in a highly regulated conversation, sensitive to outside influence and internal feedback.
MicroRNAs function as part of a ribonucleoprotein complex- MicroRNAs act as imperfect
sequence guides to recruit a ribonucleoprotein (RNP) complex to the complementary RNA. Using this
paradigm, microRNAs act in a similar manner to other RNA components of RNPs, namely to provide
a sequence-specific binding component to allow the RNP to act on a particular target. This is
conceptually similar to mRNA splicing, where small nuclear RNAs (U1, U2 and U4-6) act through
complementarity to sequences at the splice and branch sites within the intron that determine mRNA
splicing. Small nuclear RNAs are bound to proteins and the resulting RNP (snRNP) directs splicing1.
In the case of snRNPs, the recognition sequences for splicing are often ~7-8 nucleotides long and
allow occasional sequence mismatches and bulges.
The microRNA RNP complex is called the RNA-induced silencing complex (RISC), and similar to
snRNPs, the RISC uses a small RNA (microRNA) to direct sequence-specific recruitment of the RISC
to its target RNA. For microRNA-dependent targeting, often ~7-8 bases of complementarity are
sufficient (though longer stretches of complementarity can enhance binding). Again, bulges and G:U
wobble pairing are often allowed. The word ‘silencing’ in RISC can give the wrong impression for a
complex that more often acts to dampen and fine-tune expression instead of all-out silencing.
On or off- Conceptually and mechanistically related to RNA interference (RNAi) and siRNA,
microRNAs can direct repression of target genes. The mechanisms by which microRNA
complementarity to its target mediates repression are diverse2. In some cases, the microRNA binds
with complementarity in the seed region (nucleotides 2-8 of the microRNA) as well as base pairing in
the central region (bases ~9-12) causing mRNA cleavage and subsequent degradation. This
sequence-specific degradation depends on RNA hydrolysis resulting in robust silencing3. Because
this endonucleolytic cleavage occurs at the phosphoester bond joining the target nucleotides that are
opposite the microRNA bases 10-114 and mismatches in this region are not well tolerated with regard
to cleavage5, it has been generalized that microRNA-target interactions with high degrees of
complementarity result in mRNA degradation while microRNA-target interactions with less
complementarity function through translational repression. This simplification overlooks the data
showing that microRNAs can cause target degradation without cleaving the target opposite position
10-116. Thus, many microRNA targets are degraded even though they lack extensive
complementarity.
Terms like silencing and even targeting suggest that repression of the target by a microRNA is either
‘on’ or ‘off’. Generally, microRNAs do not act to completely silence their target genes, but rather
decrease expression7,8. Similarly, microRNAs themselves are sometimes considered in this binary
model to either be on or off. Indeed, there are examples where microRNAs have remarkable tissue
specificity (e.g., miR-122 in the liver or miR-124 in the brain9). There are also instances of strong
induction of microRNAs at specified developmental times (e.g., let-7 in C.elegans development10).
However, more often microRNAs are expressed in multiple cell and tissue types and have different
expression levels, but rarely fit the dichotomous scheme of ‘on or off’9.
Decreasing target expression- There are many reports of the mechanisms by which microRNAs
reduce expression of their cognate target proteins. This can include RNA degradation, as above11.
Also, induced decapping, induced deadenylation, altered cap protein binding, reduced ribosome
occupancy, and sequestration of the mRNA from translational machinery are reported. These
mechanisms are not mutually exclusive and some result in decreased mRNA levels while others act

only to decrease protein expression. The relative contribution of mRNA degradation and translational
repression was tested using microarray and ribosome profiling assays and it was found that the
majority of the microRNA effect was mediated through decreased target mRNA levels12. The practical
result of this observation is that mRNA levels can be used to indicate microRNA targeting. However,
because the magnitude of change in mRNA level is small and not all targets showed decreased
mRNA levels, the use of only mRNA profiling to determine microRNA targets may still miss relevant
target genes.
A model where microRNAs cause decreased expression of their targets is well-supported. However,
not all functional microRNA interactions involve a reduction in the expression of the target gene. For
example, miR-373 has sequence complementarity to the promoter sequence of both E-cadherin and
cold-shock domain-containing protein C2 (CSDC2). Transfection to increase levels of mature miR373 caused increased mRNA expression of E-cadherin and CSDC2 by increased promoter
occupancy by RNA Pol II13. Increased expression of TNF-α protein due to microRNA-mediated
recruitment of RISC to the AU-rich element in the 3’ untranslated region (3’UTR) of the TNF-α mRNA
during cell cycle arrest was reported, suggesting that microRNAs can have stimulatory effects on
expression depending on the timing within mitosis14. Further, repression of the miR-122 target gene
cationic amino acid transporter-1 (CAT1) was reversed in cells subjected to stress by amino acid
depletion, thapsigargin, or arsenite treatment15. Binding of RISC to the target mRNA has the potential
to displace other repressive RNA binding proteins and through this type of mechanism miR-466l
increased the expression of the cytokine IL-10. The IL-10 mRNA, like many cytokine mRNAs, is
targeted for degradation by proteins, such as tristetraprolin, that bind the AU-rich elements (ARE)
located in the IL-10 3’UTR16. IL-10 expression was thus increased by miR-466l outcompeting
tristetraprolin binding at the 3’UTR of IL-10. Loss of tristetraprolin-directed degradation resulted in
microRNA-directed increase in IL-10 expression17. The predominant mode of microRNA function
remains to decrease expression of targets with microRNA binding sites in the 3’UTR, but these
reports demonstrate that under certain cellular conditions, the repressive function of microRNAs can
be overcome; microRNA binding to the promoter can even increase target expression.
Finding microRNA targets- Sequence complementarity between the microRNA and its target is
preferentially located at the 5’ end of the microRNA, termed the seed18. The seed consists of
nucleotides 2-8, counting from the microRNA 5’ end. Complementarity at the 6-mer site from
nucleotides 2 to 7 is generally not sufficient for target repression, but one base of additional
complementarity at position 8 decreased target expression19. The definition of the canonical seed
binding site consisting of an A at position 1 followed by complementary bases over the subsequent 7
positions is useful for predicting microRNA targets18 but there are many functional targets that lack
the canonical seed binding site. These include targets with G:U wobble pairing or bulges within the
seed, illustrated by one of the original let-7 binding sites in lin-4110. A particular type of pivoting at the
seed binding site resulting in a G bulge in the seed binding site for miR-124 was even found to be a
preferred microRNA target20. Other target sites lack the seed binding site altogether and instead rely
on centered pairing21. Recently, five classes of microRNA binding sites were described using data
from many microRNA binding events. Class I sites rely only on the seed, class II sites showed seed
binding and complementarity in nucleotides 13-16 while class III sites had seed binding plus
complementarity at nucleotides 17-21. Class IV sites lack seed binding and resemble centered
pairing and class V sites had distributed or less stable binding22. The concept of the seed remains a
useful platform for understanding microRNA function but additional or alternative points of binding are
also important.
Cellular context - A frustrating aspect of microRNA research is the ability of a single microRNA to
have opposing functions in different systems, illustrating microRNA communication is context
dependent. One example is miR-125b in cancer, downregulated in multiple cancers such as
hepatocellular, breast, and lung while overexpressed in colorectal, pancreatic, gastric, and some
leukemias23. These results indicate that miR-125b has both oncogenic and tumor suppressive ability

subject to the tissue/environment. This discrepancy can be partially explained by the targets of miR125b, like p53. In certain cancer tissues, overexpression of miR-125b results in a loss of p53,
blocking apoptosis. In other tissues, p53 may be mutated and miR-125b loss will allow expression of
oncogenic targets, like epidermal growth factor receptor (EGFR) family members ERBB2/3 in breast
cancer23. Another study found the majority of microRNA targets in different cell types were not largely
different, but were more-so based upon differential 3’UTR isoforms and landscape24. An additional
concept in microRNA communication is how they interact together to target mRNAs. There are
binding sites for many microRNAs in any given mRNA 3’UTR, allowing microRNAs to work together
to increase repression of the target. In the pancreas, miR-375, miR-124 and let-7b were shown to
work together to enhance myotrophin targeting25. When the microRNAs are available to act in a
coordinated manner, there is greater repression of the target mRNA.
Regulation of microRNAs – MicroRNAs are regulated by mechanisms similar to other RNAs, such
as transcriptional activation or inhibition, epigenetic repression, and controlled degradation rates.
Roughly half, 52%, of human microRNAs are located in intergenic regions, 40% lie within intronic
regions of genes, and the final 8% are exonic26. Intronic microRNAs are often regulated by their host
gene, and processed from the intron, but may have a distinct promoter region. Intergenic microRNAs
typically have independent promoter elements. Upstream signaling initiates transcription of microRNA
genes and may create feedback loops by targeting their own transcription factor(s). MiR-200c is
involved in the epithelial-to-mesenchymal transition and is transcriptionally repressed by zinc finger Ebox-binding homeobox 1 (ZEB1)27. However, if miR-200c is overexpressed it targets ZEB1 allowing
for transcription, creating a forward-feedback loop. This shows us that microRNAs can indirectly
regulate their transcription. Processing of microRNAs by Drosha/DGCR8 in the nucleus creates
precursor microRNAs with a 3’ overhang. Dicer/TRBP in the cytoplasm recognizes this 3’ overhang
and further cleaves precursor forms to mature microRNAs. Both of these cleavage steps are reliant
on the loop and secondary structure of the microRNA, differences in these alter processing28. Further
alterations, as described below, alter the processing efficiency and recognition of microRNAs. The
half-life of microRNAs is generally long and many can persist for 5 days or longer; however some
microRNAs have rapid turnover29. Multiple factors can account for the stability of microRNAs, some of
which will be discussed below.
MicroRNAs as diagnostic markers and identifiers - MicroRNA expression profiles differ between
disease states and normal tissue. Multiple studies have used microRNAs as diagnostics, either alone
or in combination with other known biomarkers. Initial studies examining microRNA expression used
tissues to determine functional and diagnostic roles of microRNAs. However, bodily fluids are more
readily available and less invasive (in some instances) than biopsies. MicroRNAs are secreted by
cells through exosomes and extracellular vesicles30, and secreted microRNAs remain stable in bodily
fluids31. MicroRNAs have been isolated from blood (serum and plasma), saliva, urine, feces, follicular
fluid, synovial fluid, pancreatic juice, bile, gastric juice, and other bodily fluids, and are being
examined for utility as biomarkers for related diseases (Figure 1). A relevant example is microRNA
profiling of bile to identify cholangiocarcinoma at an early stage32. Bile from cholangiocarcinoma and
control patients was assayed for the presence of microRNAs. They discovered a 5-microRNA panel
that predicted early tumors better than carbohydrate antigen (CA19-9), with an overall sensitivity of
67% and specificity of 96%. Combining the microRNA panel with CA19-9, sensitivity increased to
89.7%. This panel was also able to identify patients without metastatic lymph nodes better than
CA19-9, indicating the ability to detect tumors at an early stage. MicroRNAs also have the ability to
indicate the cell type being analyzed. The most well-known example of this is the liver-specific
microRNA, miR-12233. MiR-122 plays a role in cholesterol metabolism, hepatocellular carcinoma and
hepatitis C virus infection34. Other tissue specific microRNAs include miR-134 and miR-124a in the
brain35, and miR-1 and miR-133 in the muscle36.
MicroRNA targets – MicroRNAs have the potential to target hundreds of mRNAs due to the
imperfect complementarity needed for binding. Indeed, RNA-sequencing for microRNA targets has

identified hundreds of targets for a single microRNA22. This creates a challenge identifying the
functional role of microRNAs. One way to address the function of a microRNA, or family of
microRNAs, is to determine a pathway or cellular function it most likely alters using predictive
methods. MiR-21 has become well known in the cancer field and is overexpressed in the majority of
human cancers. Its major role is inhibiting apoptosis, and miR-21 targets multiple proteins in both the
intrinsic and extrinsic pathway leading to caspase activation37,38. Another example of a microRNA
affecting multiple proteins to fine-tune pathway function is observed in miR-14 signaling. Basal levels
of miR-14 in Drosophila cells allow targeting of Hedgehog, a signaling protein involved in
development, differentiation and proliferation39. However, increased miR-14 allows targeting of
Patched and Smoothened, both members of the Hedgehog signaling pathway for a net decrease in
Hedgehog signaling. This type of regulation by microRNA expression levels permits either a passive
voice (one or few targets) in cellular communication or a more dominant role (multiple targets in
pathway).
So far, we have described microRNAs communicating in a single cell context; however microRNAs
have the ability to communicate with other cells or tissues. As discussed above, microRNAs are
secreted into exosomes or microvessicles. These secreted microRNAs are very stable and can be
taken up by cells in the surrounding tissue, or if the vesicles reached circulation, they can reach
distant sites41. MiR-150 was shown to be secreted by blood and monocytic cells and distributed to
endothelial cells, conferring functional targeting of c-Myb42. This is just one of many recent examples
of how microRNAs communicate with their surroundings.
MicroRNA family members - MicroRNAs likely originated from duplication events43, allowing for
replication of identical or similar microRNAs. MicroRNAs that have highly similar sequence and
secondary structure are considered to be family members. Because of these similarities, microRNAs
in the same family often have overlapping targets allowing for more robust repression of target
pathways. The miR-17~92 cluster is a polycistronic microRNA that is comprised of 6 microRNAs:
miR-17, -18, -19a, -20, -19b, and -92. This cluster is involved in development and overexpressed in
multiple cancers 44. The miR-17~92 cluster has two paralogs, miR-106a~363 (miRs-106a, -18b, -20b,
-19b-2, -92a-2, and -363) and miR-106b~25 (miRs-106b, -93, and -25). Out of these paralogs (13
distinct microRNAs), there are four families: miR-17 family (miRs-17, -20a, -106a, -20b, -106b and 93), miR-18 family (miRs-18a and b), miR-19 family (miRs-19a and b), and miR-92 family (miRs-92a,
- 363 and -25). Sequence similarity would propose similar function, however it was found that miR17~92, was necessary for mouse development, while miR-106a~363 or miR-106b~25 were not.
However, deletion of both miR-17~92 and miR-106b~25 showed a more severe dysfunction in B cell
development45,46. This study showed that microRNA family members have individual and overlapping
functions, broadening the complexity of microRNA function.
Modified microRNAs - Post-transcriptional modifications of microRNAs were once thought to be
rare, however, it appears that these modified microRNAs (termed isomiR) are more common than
once thought. Modifications of the 3’ end of mRNAs alter the stability of the RNA, primarily by
allowing for the decapping of the 5’ end followed by exonuclease degradation46. Modification of
microRNAs has been shown to have multiple roles. Uridylation can occur on both precursor
microRNAs (pre-miR) and mature microRNAs. One example is with Lin28, an RNA-binding protein
known to regulate let-7. Lin28 was associated with oligouridylation on the 3’ end of pre-let-7.
Oligouridylation inhibited Dicer recognition and cleavage, signaling microRNA degradation47.
However, when pre-let-7 was mono-uridylated, there was an increase in Dicer activity resulting in
higher levels of mature let-748. Mono-uridylation of some let-7 precursor microRNAs increases the
single nucleotide 3’ overhang to 2 nucleotides, allowing better recognition by Dicer. The addition of
uridine is common among other microRNA family members as well49. In addition to precursor
modification, mature microRNAs can also have 3’ nucleotide additions. MiR-26 targets Il-6 through
canonical microRNA binding of the 3’UTR. However, uridylation of miR-26a inhibits regulation of Il650. In addition to 3’ uridylation, 3’ adenylation is also present on microRNAs and has been shown to

either stabilize or degrade microRNAs. Specifically in the liver, mature miR-122 is 3’ adenylated by
PAP associated domain containing 4 (PAPD4), a poly(A) polymerase, which increased stability51.
However, when miR-21 is adenylated by PAP associated domain containing 5 (PAPD5) it is
degradated52. Although these 3’ modifications of the microRNA affect stability, they likely do not alter
mRNA targeting.
Other RNA editing of primary microRNA transcripts as well as precursors occurs, like adenosine
deamination to inosine. This alteration not only changes the nucleoside, but also the structure of the
precursor microRNA; inosine preferentially base pairs with cytidine, while adenosine preferentially
binds uridine, thus causing new mismatches and bulges. Alterations in the secondary structure of
microRNAs has the ability to alter the way RNA-binding proteins may interact, potentially inhibiting
Drosha or Dicer processing of the primary and precursor forms53,54. For example, pri-miR-151 can
have adenosine to inosine RNA editing which completely blocks recognition and cleavage by dicer54.
If the modified primary or precursor microRNA is processed to a mature microRNA and the base
substitution is in the seed region (or other highly regulatory area of the microRNA), target
specification may be altered. Similarly for miR-376, adenosines are deaminated in the seed region,
the modified miR-376 can bind alternate targets55.
In addition to 3’ modifications and deamination, the 5’ end of microRNAs can also have alternatives.
The 5’ end of microRNA is of great importance of the function of the majority of microRNAs as it
contains the seed region. Trimming of the 5’ end allows for seed-shifting and alteration of potential
mRNA targets. Differential Drosha cleavage of pri-miR-142 results in multiple 5’ shifts, -1, +1 and
+256. The alterations in the 5’ end of miR-142 likely change the seed sequence and mRNA targets.
Alternative splicing and polyadenylation of target transcripts- MicroRNA-based regulation of
gene expression commonly occurs through microRNA binding to the 3’ untranslated region of the
target mRNA. The length of the 3’UTR is a feature of the target gene, but can be altered through the
use of alternative cleavage and polyadenylation signals (PAS). The PAS generally consists of a
hexanucleotide 5’AAUAAA, but single base variants are described. Commonly, after the termination
codon a gene will have multiple AAUAAA-like sequences, allowing for alternative usage. Alternative
polyadenylation can shorten or lengthen the 3’UTR depending on whether an upstream signal
becomes active or if the canonical PAS is skipped and a downstream signal is employed (Figure 2).
Thus, alternative polyadenylation can result in the loss or gain of microRNA binding sites, a concept
with experimental support57-59. Interestingly, the miR-21 precursor sequence is located downstream of
the gene for vacuole membrane protein-1 (VMP1) on the same strand, a few hundred bases distal to
the PAS. MiR-21 is expressed at elevated levels in cancer and has oncogenic effects. Recently,
skipping of the VMP1 PAS and use of an alternate distal sequence was shown to increase miR-21
expression by including the pre-mir-21 sequence in the 3’UTR of VMP160.
Similar to the inclusion or exclusion of microRNA binding sites through alternative polyadenylation,
alternative splicing has the potential to alter both the coding and UTR sequences of target mRNAs
and thus alternative splicing has the potential to change microRNA binding potential. While alternative
splicing is understood to alter the coding region of an mRNA, alternative usage of splice sites at the 3’
end of the transcript can result in completely different 3’UTR sequences for otherwise related
mRNAs. As an example, the gene LMNA encodes both Lamin A and Lamin C, with Lamin A resulting
from alternative splicing that results in inclusion of two additional exons and a novel 3’UTR compared
to Lamin C. The protein products are identical for most of the protein with only a short C-terminal
extension on Lamin A distinguishing the two. However, because the mRNAs each have different
3’UTR sequences, only Lamin A is regulated by the brain-specific miR-961. MicroRNAs encoded
within introns of either coding or non-coding host genes are processed without regard for splicing62
suggesting that alternative splicing would not necessarily alter microRNA expression. However, there
are microRNAs that span the exon-intron splice site and are responsive to splicing. For example,
miR-412 is one of several microRNAs encoded on the long non-coding RNA (lncRNA) Mirg63 and the
pre-miR-412 stem loop overlaps a splice site. Splicing interrupts the stem-loop of miR-412 preventing

processing to pre-mir-412 resulting in decreased miR-412 expression. On the other hand, skipping of
the exon maintains the stem-loop and allows processing and expression. Alternative splicing of this
lncRNA has a direct effect on expression of the microRNAs it contains64. Alternative polyadenylation
or alternative splicing can both change the conversation by affecting the responsiveness of the target
gene to microRNA binding (presence or absence of the binding site) or by changing the level of the
microRNA itself (i.e., miR-21 and miR-412).
Single-nucleotide polymorphisms - Single nucleotide polymorphisms (SNP) are relatively common
base variances in which a base substitution is inherited; generally there are only two alleles at the
particular site- the common sequence and the SNP (present in ~1-5% of individuals). Because SNPs
are inherited and are physically linked to the neighboring genetic material, most do not change the
cellular phenotype but may be used as a marker of disease when a nearby gene carries a mutation
(often the offending mutation is unknown and the SNP acts as a convenient means to infer the local
change). However, a number of SNPs do change the function of their host gene; some also alter
microRNA function or expression.
A single base change could impact microRNA function in a number of ways. For example, a SNP
may unmask a cryptic microRNA binding site in the variant allele, resulting in a new functional
interaction. Alternatively, if the variant alters a functional microRNA binding site, it may result in loss
of microRNA-mediated regulation of the variant allele (Figure 2). In either case, for a patient with one
of each allele, the result may be preferential expression of either the maternal or paternal allele of the
gene.
An example of a disease-related SNP that regulates microRNA function by altering a microRNA
binding site was found in the 3’UTR of KRAS. The allele resides in a binding site for let-7, and cells
harboring a KRAS allele with the variant expressed higher levels of KRAS. Importantly, the variant
was found in 18-20% of patients with non-small cell lung cancer, but only 6% of the general
population65. There are now bioinformatic resources to explore the effects of SNPs on microRNA
sequence and binding sites66,67.
Regulation of non-coding RNAs by microRNAs - Considering the model of microRNAs as a
sequence-specific guide to recruit the RISC to a target RNA, there is no a priori reason that the target
must be a protein coding mRNA. MicroRNAs are one component of a class of RNA called non-coding
RNAs (ncRNAs). In addition to microRNAs, there are many types of ncRNAs, including lncRNAs.
Complementarity between microRNAs and other ncRNAs has been identified to be part of the
conversation involving microRNAs and cell signaling. A few examples follow, with the note that there
are more examples than those listed and systematic efforts are underway to catalog these
interactions.
A direct functional relationship between lncRNAs and microRNAs was demonstrated previously in
chronic lymphocytic leukemia68. Recently, additional examples of microRNAs that directly bind to
sequences in lncRNAs causing repression have been described. For example, metastasis associated
lung adenocarcinoma transcript 1 (MALAT1) is expressed at increased levels in several cancer types
and was found to be negatively correlated with miR-125b expression levels in bladder cancer. The
effect was direct, due to sequence complementarity between miR-125b and MALAT1 and the effects
of increasing miR-125b were similar to the phenotype seen in cells with MALAT1 knockdown69.
Similarly, the non-coding RNA HCA1 is overexpressed in bladder cancer while miR-1 is expressed at
a lower level in this cancer. This inverse relationship suggests that miR-1 may repress HCA1
expression, and indeed, there is a functional miR-1 binding site in HCA1. HCA1 repression was
dependent upon Argonaute 2 expression, consistent with functional reduction of HCA1 by miR-1
through the RISC70.
Evidence that mature microRNAs in the RISC can bind to other mature microRNAs was captured
using a technique called CLASH, cross-linking, ligation, and sequencing of hybrids. By
immunopurifying RNAs bound to RISC followed by partial digestion and RNA-RNA ligation, the

authors were able to identify microRNAs and their cognate targets through the production of chimeric
RNA molecules. Non-coding RNAs made up 26% of the identified microRNA targets. One interaction
highlighted was the binding of let-7 family members with mature miR-30b and miR-30c. Let-7 and
miR-30 microRNAs have imperfect sequence complementarity to each other across most of their
respective sequences (Figure 3). Additional ncRNA targets included tRNAs, rRNAs, and
pseudogenes22. In addition to mature microRNAs, let-7 can bind and regulate primary microRNA
transcripts. Mature let-7, in complex with the C. elegans argonaut protein was identified in the nuclear
fraction where it bound to unprocessed pri-let-7. This interaction stimulated subsequent RNasedependent processing of pri-let-7, resulting in a positive feedback role; let-7 functioned to further
increase levels of mature let-771.
Another example of ncRNA regulation of microRNA processing involves an lncRNA with an
ultraconserved region and miR-195. Cleavage of pri-mir-195 by Drosha is regulated by Uc.283+A.
Uc.283+A has a short (11 nucleotides) region of complementarity to pri-mir-195 at the sequence
immediately upstream of the Drosha cleavage. Binding of Uc.283+A to pri-miR-195 decreased
microRNA processing presumably by altering the structural recognition of the stem loop by the
Drosha-containing microprocessor complex, resulting in decreased expression of mature miR-195 in
the presence of Uc.283+A72. MicroRNAs can also affect the expression of lncRNAs indirectly. For
example, miR-29 indirectly increased the expression of the lncRNA MEG3 in HCC by microRNAmediated reduction of the DNA methyltransferases DNMT1 and 3b, resulting in loss of epigenetic
silencing of MEG373.
In conclusion, microRNAs can affect lncRNA expression directly or indirectly to alter cellular function.
Not surprisingly, lncRNAs can also affect microRNA expression through sequence-specific binding
that alters processing. Finally, microRNA-microRNA interaction in the RISC is reported. Short
stretches of imperfect complementarity between microRNAs and their targets are sufficient to
promote a functional interaction, suggesting that other interactions will be described. Known and
predicted microRNA-lncRNA interactions are maintained in a searchable database, DIANALncBase74.
Conclusions- MicroRNAs function as sequence-specific guides to direct a functional RNP to the
target RNA of interest. When the target is a protein-coding mRNA, the most likely outcome of
microRNA binding is decreased target protein expression. However, the effect is usually not to
silence expression, but rather a more nuanced effect to decrease protein levels. This can be amplified
by binding multiple microRNAs to a single target, or by the targeting of multiple proteins in the same
pathway. When the target is a ncRNA, microRNA binding can also negatively affect expression of the
target RNA. Similarly, ncRNAs can bind to the primary microRNA positively or negatively influencing
processing and expression of the mature microRNA. We have begun to conceptualize microRNA
function as a conversation within the cell. The discussion is generally not limited to a true/false or
on/off effect of microRNAs but is more like a drawn-out conversation. Expression of the microRNA
itself is influenced by many participants in the conversation, at the level of transcription, processing,
and function. Expression of the target RNA is likewise regulated at numerous levels by microRNAs,
including epigenetic effects, promoter regulation, RNA processing and stability, and translation. The
conversation was first noticed between microRNAs and protein-coding mRNAs, but is now
recognized to be held between microRNAs and many other types of RNAs. Finally, the conversation
is not limited to the cell where it began, as cell-cell transfer of microRNAs has functional effects on
the downstream cell of interest. Just as in life, participants in the microRNA conversation come and
go, whisper or shout, and have a positive or negative impact on others around them. We look forward
to listening in as this cellular dialog continues; we are especially keen to learn how microRNAs can be
used to steer the talk away from disease and toward health.
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Figure Legends

Figure 1. MicroRNAs as biomarkers and prognostic factors. MicroRNAs are secreted into various
bodily fluids which can be altered by disease states. Current studies are attempting to utilize
microRNAs in these fluids for diagnostic and prognostic value. Examples are listed in this diagram:
cerebrospinal fluid, Alzheimer’s disease1; vitreous humor, ocular diseases2; saliva, esophageal
cancer3; blood, cardiovascular disease4; bile, cholangiocarcinoma5; gastric juice, gastric cancer6;
pancreatic juice, pancreatic cancer7; urine, renal fibrosis8; fecal matter, colon cancer9; synovial fluid,
Rheumatoid arthritis10.

Figure 2. Alternative microRNA targeting. Multiple instances may arise in which microRNAs can no
longer bind to their intended targets. Three examples are: 1) Alternative splicing - the microRNA
binding site is spliced out of the target transcript; 2) Alternative polyadenylation signals - short 3’UTRs
lack the microRNA binding site; and 3) Single nucleotide polymorphisms - altered microRNA binding
sequence in the target mRNA inhibiting binding site recognition.

Figure 3. MicroRNA-microRNA binding. Mature microRNAs can bind in a sequence-specific
manner to each other, as demonstrated by cross-linking, ligation and sequencing of hybrids (CLASH).
Illustrated here is the antiparallel microRNA duplex containing let-7a and miR-30c, adapted from
Helwak et al., 2013. The 5’ terminus and seed region of each microRNA is indicated in yellow
(nucleotides 1-8) and the remaining microRNA is in grey. Vertical ‘ladder rungs’ indicate WatsonCrick base pairing, while the absence of a rung indicates a mismatch (i.e., within the miR-30c seed).
Single nucleotide bulges (either symmetric or asymmetric) are depicted as a triangular deviation of
the backbone.

